目的 探讨基线全身炎症反应指数(systemic inflammatory response index,SIRI)对腹膜透析(peritoneal dialysis,PD)患者腹膜透析相关性腹膜炎(peritoneal dialysis-related peritonitis,PDAP)发生和预后的预测价值。 方法 回顾性分析2014年1月—2020年12月于安徽医科大学第二附属医院行PD置管的140例患者为研究对象，根据是否发生PDAP分为腹膜炎组和非腹膜炎组，比较2组患者一般临床资料及实验室指标。采用二分类Logistic回归分析PDAP发生的危险因素，采用受试者工作特征(ROC)曲线评估基线SIRI对PDAP发生的预测价值。根据腹膜炎组的预后情况将其进一步分为治疗成功组与治疗失败组，分析腹膜炎治疗失败的危险因素。 结果 腹膜炎组的SIRI(Z=-4.347，P＜0.001)、白细胞计数(Z=-3.590，P＜0.001)、血磷(Z=-5.499，P＜0.001)、血清碱性磷酸酶(Z=-2.452， P =0.014)、总胆固醇(Z=-2.195，P=0.028)水平高于非腹膜炎组，差异有统计学意义。多因素Logistic回归分析显示：基线高SIRI(OR=2.084,95% CI：1.054～4.121,P=0.035)、高血磷(OR=11.826,95% CI：4.204～33.262,P＜0.001)及高血清碱性磷酸酶(OR=1.010,95% CI：1.002～1.019,P=0.022)是PDAP发生的危险因素。ROC曲线结果显示SIRI的曲线下面积为0.720(95% CI：0.633～0.808,P＜0.001)，灵敏度和特异度分别为69.2%和67.0%。高基线SIRI水平(OR=0.446,96% CI：0.208～0.959,P=0.039)是PDAP治疗失败的危险因素。 结论 基线全身炎症反应指数与维持性腹膜透析患者发生腹膜透析相关性腹膜炎发生风险相关，对腹膜透析相关性腹膜炎的发生和预后有较好的预测价值。
Objective To investigate the predictive value of baseline systemic inflammatory response index (SIRI) for peritoneal dialysis-associated peritonitis (PDAP) in peritoneal dialysis (PD) patients. Methods A total of 140 patients undergoing PD catheterization in the Second Affiliated Hospital of Anhui Medical University from January 2014 to December 2020 were retrospectively analyzed. They were divided into peritonitis group and non-peritonitis group according to the presence or absence of PDAP. General clinical data and laboratory indexes were compared between the two groups. Binary logistic regression was used to analyze the risk factors for PDAP, and receiver operating characteristic (ROC) curve was used to evaluate the predictive value of baseline SIRI for the occurrence of PDAP. According to the prognosis in peritonitis group, the patients were further divided into a successful treatment group and an ineffective treatment group; the risk factors for peritonitis treatment failure were then analyzed. Results SIRI (Z=-4.347, P<0.001), white blood cell count (Z=-3.590, P<0.001), serum phosphorus (Z=-5.499, P<0.001), serum alkaline phosphatase (Z=-2.452, P=0.014), and total cholesterol (Z=-2.195, P=0.028) were significantly higher in the peritonitis group than in the non-peritonitis group. Multivariate logistic regression showed that higher SIRI (OR=2.084, 95% CI: 1.054～4.121, P=0.035), higher serum phosphorus (OR=11.826, 95% CI: 4.204～33.262, P<0.001) and higher serum alkaline phosphatase (OR=1.010, 95% CI: 1.002～1.019, P=0.022) were the risk factors for PDAP. ROC curve showed that the area under the curve of SIRI was 0.720, with the sensitivity of 69.2% and specificity of 67%. Higher baseline SIRI level (OR=0.446, 96% CI: 0.208～0.959, P=0.039) was a risk factor for treatment failure of PDAP. Conclusions The baseline SIRI is associated with the risk of PDAP in PD patients, and is a good predictive indicator for the occurrence and prognosis of PDAP.
[1] BELLO A K, OKPECHI I G, OSMAN M A, et al. Epidemiology of peritoneal dialysis outcomes [J]. Nat Rev Nephrol, 2022, 18(12): 779-93.
[2] PERL J, FULLER D S, BIEBER B A, et al. Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) [J]. Am J Kidney Dis, 2020, 76(1): 42-53.
[3] DZEKOVA-VIDIMLISKI P, NIKOLOV I G, GJORGJIEVSKI N, et al. Peritoneal Dialysis-Related Peritonitis: Rate, Clinical Outcomes and Patient Survival [J]. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2021, 42(3): 47-55.
[4] WANG R H, WEN W X, JIANG Z P, et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage [J]. Front Immunol, 2023, 14: 1115031.
[5] CAO Y, ZHENG X, HU Y, et al. Levels of systemic inflammation response index are correlated with tumor-associated bacteria in colorectal cancer [J]. Cell Death Dis, 2023, 14(1): 69.
[6] KUCUK A, OZKAN E E, ESKICI OZTEP S, et al. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy [J]. J Oncol, 2020, 2020: 8832145.
[7] LI J, LI Y, ZOU Y, et al. Use of the systemic inflammation response index (SIRI) as a novel prognostic marker for patients on peritoneal dialysis [J]. Ren Fail, 2022, 44(1): 1227-35.
[8] LI P K, CHOW K M, CHO Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment [J]. Perit Dial Int, 2022, 42(2): 110-53.
[9] HTAY H, CHO Y, PASCOE E M, et al. Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry [J]. Am J Kidney Dis, 2018, 71(6): 814-21.
[10] BARONI G, SCHUINSKI A, DE MORAES T P, et al. Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis [J]. Mediators Inflamm, 2012, 2012: 912595.
[11] SUTHERLAND T E, SHAW T N, LENNON R, et al. Ongoing Exposure to Peritoneal Dialysis Fluid Alters Resident Peritoneal Macrophage Phenotype and Activation Propensity [J]. Front Immunol, 2021, 12: 715209.
[12] JIANG C, ZHANG S, QIAO K, et al. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy [J]. Clin Breast Cancer, 2022, 22(5): 424-38.
[13] HAN K, SHI D, YANG L, et al. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention [J]. Ann Med, 2022, 54(1): 1667-77.
[14] KRAUS R F, GRUBER M A. Neutrophils-From Bone Marrow to First-Line Defense of the Innate Immune System [J]. Front Immunol, 2021, 12: 767175.
[15] MORO-GARCIA M A, MAYO J C, SAINZ R M, et al. Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes [J]. Front Immunol, 2018, 9: 339.
[16] KRATOFIL R M, KUBES P, DENISET J F. Monocyte Conversion During Inflammation and Injury [J]. Arterioscler Thromb Vasc Biol, 2017, 37(1): 35-42.
[17] GRATEROL TORRES F, MOLINA M, SOLER-MAJORAL J, et al. Evolving Concepts on Inflammatory Biomarkers and Malnutrition in Chronic Kidney Disease [J]. Nutrients, 2022, 14(20).
[18] ZHAO Z, YAN Q, LI D, et al. Relationship between serum iPTH and peritonitis episodes in patients undergoing continuous ambulatory peritoneal dialysis [J]. Front Endocrinol (Lausanne), 2023, 14: 1081543.
[19] KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES C K D M B D U W G. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [J]. Kidney Int Suppl (2011), 2017, 7(1): 1-59.
[20] YAMADA S, TOKUMOTO M, TATSUMOTO N, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia [J]. Am J Physiol Renal Physiol, 2014, 306(12): F1418-28.
[21] MARTINEZ-MORENO J M, HERENCIA C, DE OCA A M, et al. High phosphate induces a pro-inflammatory response by vascular smooth muscle cells and modulation by vitamin D derivatives [J]. Clin Sci (Lond), 2017, 131(13): 1449-63.
[22] EREZ D, FANADKA F, BENCHETRIT S, et al. The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients [J]. Am J Nephrol, 2021, 52(9): 763-70.
[23] LIU X, GUO Q, FENG X, et al. Alkaline phosphatase and mortality in patients on peritoneal dialysis [J]. Clin J Am Soc Nephrol, 2014, 9(4): 771-8.
[24] HWANG S D, KIM S H, KIM Y O, et al. Serum Alkaline Phosphatase Levels Predict Infection-Related Mortality and Hospitalization in Peritoneal Dialysis Patients [J]. PLoS One, 2016, 11(6): e0157361.
